Our
Story
We are a pharmaceutical development
company with experienced executives
and a shared vision to improve the
standard of cancer care.
VasoDynamics is a pharmaceutical development company based in Stevenage and London, UK.
We are a young company with dynamic executives with a shared vision to improve the standard of cancer care globally.
Recognising the mounting cost pressures facing healthcare payers all over the world, we are developing a number of cost-efficient treatments, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy.
We take great pride in our culture of scientific and developmental rigour, and our programmes are based on robust science from world-leading research bodies.
Our Focus
To develop patient-friendly and preventative therapies that are very cost-effective and make a major, positive difference to cancer patients’ well-being and quality of life.
Our programs are designed to prevent the common complications of cancer therapies, including mouth ulceration, dermatitis, and (permanent) hair-loss, thereby improving both treatment outcomes and patients’ quality of life.
All our programs are being developed for topical administration, both before and during cancer treatment, for optimal patient convenience and cost effectiveness.
Topical administration and rapid onset of action both reduce the need for additional patient visits to clinic, providing opportunities for significant healthcare savings.
Our Pipeline
Our technology platform has so far generated three formulations with 5 lead products, all of which have generated compelling results in the laboratory and initial human studies.
Our Intellectual Property
This is protected by a number of global patents and is based on groundbreaking researches from global leading Universities in US and UK in the field of chemotherapy toxicology and radioprotection.
Our Team
This includes executives with decades of individual experience across Scientific Research, Drug Discovery, Medical Oncology and Clnical Oncology, Regulatory Affairs, Clinical Trials and Commercialisation.
Our Lead
Current lead programme, NG11-2 is for the prevention of severe radiotherapy-induced oral mucositis (RIOM) and due to start clinical trials in 2023.
NG12-1 for the prevention & reduction of radiotherapy-induced dermatitis has obtained Proof-of-Concept (POC) with a well-tolerated safety profile and statistically significant efficacy in an Investigator led Phase-IIa trial (trial number NCT01263366).
VasoDynamics is a pharmaceutical development company based in Stevenage and London, UK.
We are a young company with dynamic executives with a shared vision to improve the standard of cancer care globally.
Recognising the mounting cost pressures facing healthcare payers all over the world, we are developing a number of cost-efficient treatments, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy.
We take great pride in our culture of scientific and developmental rigour, and our programmes are based on robust science from world-leading research bodies.
Our Focus
To develop patient-friendly and preventative therapies that are very cost-effective and make a major, positive difference to cancer patients’ well-being and quality of life.
Our programs are designed to prevent the common complications of cancer therapies, including mouth ulceration, dermatitis, and (permanent) hair-loss, thereby improving both treatment outcomes and patients’ quality of life.
All our programs are being developed for topical administration, both before and during cancer treatment, for optimal patient convenience and cost effectiveness.
Topical administration and rapid onset of action both reduce the need for additional patient visits to clinic, providing opportunities for significant healthcare savings.
Our Pipeline
Our technology platform has so far generated three formulations with 5 lead products, all of which have generated compelling results in the laboratory and initial human studies.
Our Intellectual Property
This is protected by a number of global patents and is based on groundbreaking researches from global leading Universities in US and UK in the field of chemotherapy toxicology and radioprotection.
Our Team
This includes executives with decades of individual experience across Scientific Research, Drug Discovery, Medical Oncology and Clnical Oncology, Regulatory Affairs, Clinical Trials and Commercialisation.
Our Lead
Current lead programme, NG11-2 is for the prevention of severe radiotherapy-induced oral mucositis (RIOM) and due to start clinical trials in 2023.
NG12-1 for the prevention & reduction of radiotherapy-induced dermatitis has obtained Proof-of-Concept (POC) with a well-tolerated safety profile and statistically significant efficacy in an Investigator led Phase-IIa trial (trial number NCT01263366).